In silico analysis of atrial fibrillation and hypertension mechanism of action secondary to ibrutinib/acalabrutinib in chronic lymphocytic leukemia

In silico analysis of atrial fibrillation and hypertension mechanism of action secondary to ibrutinib/acalabrutinib in chronic lymphocytic leukemia

Abstract Ibrutinib and acalabrutinib are first- and next-generation Bruton Tyrosine Kinase inhibitors (BTKi), respectively, approved for chronic lymphocytic leukemia (CLL). Ibrutinib has been associated with cardiovascular events, including atrial fibrillation (AF) and hypertension. Acalabrutinib ha...

Full description

Saved in:
Bibliographic Details
Main Authors: Raúl Córdoba, Antoni Bayés-Genís, Ana Muntañola, Dolors Colomer, Jorge Castro, Carolina Leiva, Esther Álvarez, Eduardo Zatarain-Nicolas
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Bruton’s tyrosine kinase inhibitors
Ibrutinib
Acalabrutinib
Atrial fibrillation
Hypertension
Chronic lymphocytic leukemia.
Online Access:https://doi.org/10.1038/s41598-025-07756-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-07756-2

Similar Items